Self-Assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid
Abstract
A drug carrier based on glycyrrhetinic acid-modified sulfated chitosan (GA-SCTS) was synthesized. The glycyrrhetinic acid (GA) acted as both a hydrophobic group and a liver-targeting ligand. The GA-SCTS micelles displayed rapid and significant ability to target the liver in vivo. The IC50 for doxorubicin (DOX)-loaded GA-SCTS micelles (DOX/SA-SCTS micelles) against HepG2 cells was 54.7 ng/mL, which was extremely lower than the amount of no-GA-modified DOX-loaded micelles. In addition, DOX/SA-SCTS micelles could target specifically the liver cancer cells. They had higher affinity for the liver cancer cells (HepG2 cells) than for the normal liver cells (Chang liver cells). There was nearly 2.18-fold improvement in uptake of the DOX/SA-SCTS micelles by HepG2 cells than that by Chang liver cells. These results indicate that GA-SCTS is not only an excellent carrier for drugs, but also a potential vehicle for liver-cancer targeting.
Graphical Abstract
Glycyrrhetinic acid (GA)-modified carriers are more efficient for liver- or hepatocyte-targeted delivery; however, less information is available about their biodistribution, and there is no information that GA-modified drug delivery system has the ability to target specifically the liver cancer cells. Therefore, GA-modified sulfated chitosan (GA-SCTS) polymeric micelles were designed and prepared in this work. The biodistribution and in vitro cellular uptake assays were investigated. GA-SCTS micelles had several advantages, such as the low CAC (critical aggregation concentration) value, high encapsulation efficacy, and high loading content for doxorubicin (DOX). In addition, they displayed rapid and significant ability to target the liver in vivo. It is important to note that GA-SCTS micelles had higher affinity for HepG2 cells (liver cancer cells) than for Chang liver cells (liver normal cells).
Key words: Sulfated chitosan, Glycyrrhetinic acid, Polymeric micelles, Drug delivery, Liver targeting
To access this article, please choose from the options below
The authors report no conflict of interest.
This work is financially supported by the National Natural Science Foundation of China (No. 50873048, 51073080), Key Project of Scientific and Technical Supporting Programs of Tianjin (No. 10ZCKFSY07500), and State Key Fundamental R and D Project (No. 2011CB606202).
PII: S1549-9634(11)00519-3
doi:10.1016/j.nano.2011.11.002
© 2011 Elsevier Inc. All rights reserved.
